These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1150 related items for PubMed ID: 12713061

  • 21. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M, Opravil M, von Wyl V, Hirschel B, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Battegay M, Yerly S, Günthard H, Bucher HC, Swiss HIV Cohort Study.
    AIDS; 2007 Oct 18; 21(16):2201-7. PubMed ID: 18090047
    [Abstract] [Full Text] [Related]

  • 22. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P, Lang J, DeJesus E, Berger DS, Dretler R, Rodriguez A, Ward DJ, Lim ML, Liao Q, Reddy S, Clair MS, Vila T, Shaefer MS.
    HIV Clin Trials; 2006 Oct 18; 7(5):229-36. PubMed ID: 17162316
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R.
    AIDS; 2007 Jan 30; 21(3):325-33. PubMed ID: 17255739
    [Abstract] [Full Text] [Related]

  • 26. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R, Calza L, Chiodo F.
    HIV Clin Trials; 2005 Jan 30; 6(6):302-11. PubMed ID: 16452064
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V, EFADITE Study Group.
    Antivir Ther; 2005 Jan 30; 10(7):825-32. PubMed ID: 16312178
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F.
    Antivir Ther; 2014 Jan 30; 19(1):117-23. PubMed ID: 24145365
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2016 Dec 10; 12(12):CD004246. PubMed ID: 27943261
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Experience with nevirapine in previously treated HIV-1-infected individuals.
    Wit FW, Dutch HIV-treating physicians.
    Antivir Ther; 2000 Dec 10; 5(4):257-66. PubMed ID: 11142620
    [Abstract] [Full Text] [Related]

  • 37. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.
    HIV Med; 2008 May 10; 9(5):294-9. PubMed ID: 18400076
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, González-Lahoz J.
    AIDS; 2000 May 05; 14(7):807-12. PubMed ID: 10839588
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.